Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

German guideline for diagnosis and treatment of multiple sclerosis - a survey focusing neurologists in daily practise.

Multiple sclerosis and related disorders·2022
Same author

Development and evaluation of evidence-based patient information handbooks about multiple sclerosis immunotherapies.

Multiple sclerosis and related disorders·2022
Same author

Implementation study of the 2021 German guideline for diagnosis and treatment of multiple sclerosis.

Multiple sclerosis and related disorders·2021
Same author

Controversy on the treatment of multiple sclerosis and related disorders: positional statement of the expert panel in charge of the 2021 DGN Guideline on diagnosis and treatment of multiple sclerosis, neuromyelitis optica spectrum diseases and MOG-IgG-associated disorders.

Neurological research and practice·2021
Same author

[The critically ill CAR T-cell patient : Relevant toxicities, their management and challenges in critical care].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2021
Same author

Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis.

Multiple sclerosis and related disorders·2020
Same journal

[When brain abscesses run in the family…].

Der Nervenarzt·2026
Same journal

[Digital health applications and adherence in depression: a qualitative study from the perspective of healthcare providers].

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
Same journal

[Rare genetic diseases with frequent mental symptoms].

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

[Interferon β for multiple sclerosis. How much is good enough?].

C Warnke1, V I Leussink, B C Kieseier

  • 1Neurologische Klinik, Heinrich-Heine-Universität Düsseldorf, Moorenstraße 5, 40225, Düsseldorf.

Der Nervenarzt
|November 25, 2010
PubMed
Summary
This summary is machine-generated.

Interferon beta-1b (IFNB-1b) shows potential for increased efficacy at higher doses in multiple sclerosis (MS) treatment. The BEYOND trial provides new data comparing IFNB-1b with glatiramer acetate for relapsing-remitting MS.

More Related Videos

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses
10:10

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Published on: November 16, 2016

Related Experiment Videos

Last Updated: Jun 6, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses
10:10

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Published on: November 16, 2016

Area of Science:

  • Neuroimmunology
  • Clinical pharmacology
  • Therapeutic strategies for Multiple Sclerosis

Context:

  • Interferon beta-1b (IFNB-1b) was the first approved therapy for multiple sclerosis (MS).
  • Early research suggested a dose-dependent efficacy for IFNB-1b.
  • Limited clinical data existed on higher IFNB-1b dosing and direct comparisons with glatiramer acetate.

Purpose:

  • To review the BEYOND trial, a prospective, randomized, multicenter study.
  • To assess the potential of higher IFNB-1b dosing to enhance therapeutic efficacy.
  • To compare the efficacy of IFNB-1b directly with glatiramer acetate in relapsing-remitting MS.

Summary:

  • The BEYOND trial investigated higher doses of interferon beta-1b (IFNB-1b) and compared its efficacy against glatiramer acetate.
  • Results from the BEYOND trial provide crucial data on IFNB-1b dose-dependency and head-to-head comparison.
  • This review analyzes the BEYOND trial findings within the landscape of current first-line MS therapies.

Impact:

  • Provides evidence for optimizing IFNB-1b dosing in MS management.
  • Offers comparative efficacy data crucial for selecting first-line treatments for relapsing-remitting MS.
  • Informs clinical decision-making regarding interferon beta-1b and glatiramer acetate therapies.